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Volume 58, no. 4, p 2030–2037, 2014. Page 2030, right column, line 6. Since the suspension of the European marketing authorization
for telavancin has now been lifted, the following text in the introduction no longer applies: “At the time of submission, the telavancin
European marketing authorization for the treatment of nosocomial pneumonia was suspended pending evidence of a new European
Medicines Agency-approved supplier. ClinigenHealthcare Ltd., Theravance’s commercialization partner for telavancin in Europe, is in
the process of seeking approval of a new manufacturing source.”
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